ArticleClinical pharmacology and therapeutics2022

Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy.

Jessica Wojciechowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.